SynthesisJournal of Zhejiang University. Science. B2014
HER-2 overexpression and survival in colorectal cancer: a meta-analysis.
Synthesis in Journal of Zhejiang University. Science. B, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis.Diagnostic pathology · 2015Pooled it
- Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer-Predisposing Factors in Familial Early-Onset Colorectal Cancer.The Kaohsiung journal of medical sciences · 2026Article
- HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Review
- HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration.Biomedicines · 2023Article
- Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study.World journal of gastrointestinal oncology · 2022Article
- Spatial heterogeneity of cancer associated protein expression in immunohistochemically stained images as an improved prognostic biomarker.Frontiers in oncology · 2022Article
- HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer.Cancer management and research · 2021Article
- Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma.Journal of gastrointestinal cancer · 2020Review
- Expression of COX-2 and HER-2 in colorectal cancer and their correlation.World journal of gastroenterology · 2015Article
- HER2 expression in gastric and oesophageal cancer: a meta-analytic review.Journal of gastrointestinal oncology · 2015Article
- Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification.Oncoscience · 2015Article
- Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Colorectal Cancer and Its Clinical Significance among Jordanian Patients.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNumerous studies examining the relationship between human epidermal growth factor receptor 2 (HER-2) overexpression and survival in patients with colorectal cancer (CRC) have yielded controversial results. We therefore performed a meta-analysis more precisely to estimate its prognostic value.
methodsPublished studies investigating the effect of HER-2 overexpression on CRC survival were identified; the hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were pooled in terms of disease-specific or overall survival.
resultsEleven studies were included in the meta-analysis. The pooled data showed that HER-2 overexpression was negatively related to CRC survival (HR=1.10, 95% CI: 0.77-1.44). Subgroup analyses regarding test method and study quality also demonstrated little association between HER-2 overexpression and CRC survival (HR=0.89, 95% CI: 0.50-1.29; HR=0.90, 95% CI: 0.43-1.37, respectively).
conclusionsRegardless of several limitations, our study suggested that HER-2 overexpression probably had little impact on CRC survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.